15 References: 1. NCCN Clinical Practice Guidelines in Oncology, National ComprehensiveCancer Network, 2022. Available at: https://www.nccn.org 2. Supiot S, Vaugier L, Pasquier D, et al. OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer. Eur Urol 2021;80:405–414. 3. HellmanS, WeichselbaumRR. Oligometastases. J Clin Oncol. 1995 Jan;13(1):8–10. 4. Ost P, Jereczek-Fossa BA, Van As N, et al. Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences. Clin Oncol (R Coll Radiol) 2016;28:e115–20. 5. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6(5):650. 6. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.J Clin Oncol. 2020;38(25):2830. Epub 2020 Jun 2. 7. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Recurrence: A Meta-analysis.Am J Clin Oncol. 2020;43(2):73. 8. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Fiveyear results of a randomized phase II trial J Clin Oncol. 2020;38S:ASCO #10. 9. Curative-intent Metastasis-directed Therapies for Molecularlydened Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.Eur Urol. 2021;80(3):374. Epub 2021 Mar 6. 10. OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer. Eur Urol. 2021;80(4):405. Epub 2021 Jul 8. 11. Deek, M.P et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J. Clin. Oncol. 2022, 40, 3377–3382 12. NCT03902951 Antiandrogen Therapy and SBRT in Treating Patients with Recurrent Metastatic Prostate Cancer. Available onlinehttps://clinicaltrials.gov/ct2/show/NCT03902951 13. NCT03795207 Prostate Cancer with Oligometastatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736) (POSTCARD)Available online: https://clinicaltrials.gov/ct2/show/NCT0379527 14. NCT04641078 Stereotactic Body Radiotherapy with or without Darolutamide for OligoRecurrent Prostate Cancer (DART)Available online https://clinicaltrials.gov/ct2/ show/NCT04641078 15. Ct04423211 Treating Prostate Cancer that Has Come Back after Surgery with Apalutamide and Targeted Radiation Using PET/CT Imagi Available online: https://clinicaltrials.gov/ ct2/show/NCT04423211 16. Node Oligorecurrence in Prostate Cancer: A Challenge, Almudena Zapatero et al 17. Recommendations for radiation therapy in oligometastatic prostate cancer: ESTRO_ACROP Delphi consenus, October 2022 In conclusion, oligometastatic prostate cancer should be viewed as an opportunity to alter the disease trajectory of prostate carcinoma. These patients should be managed jointly in a multidisciplinary team setting for best outcomes. Radiotherapy has a proven role to offer cure and delay disease progression. UROLOGY, URO-ONCOLOGY AND SEXOLOGY UPDATE
RkJQdWJsaXNoZXIy NTIyOTQ=